Sorrento Therapeutics Inc. [NASDAQ: SRNE] price surged by 11.83 percent to reach at $1.04. The company report on March 9, 2021 that Sorrento and Mount Sinai Health System Enter Into Exclusive License Agreement for Development of Potent Antibody Combinations Aimed at Neutralizing SARS-CoV-2 and the Emerging United Kingdom and South Africa Variants of COVID-19.
Sorrento is moving forward with the research and development of COVISHIELD antibody combinations with potentially potent neutralizing activities against early COVID-19 pandemic virus isolates as well as current variants of concern.
Pre-clinical development of an antibody combination therapeutic including Sorrento and Mount Sinai antibodies for intravenous (IV) and intranasal administration is underway.
A sum of 15796174 shares traded at recent session while its average daily volume was at 18.86M shares. Sorrento Therapeutics Inc. shares reached a high of $10.13 and dropped to a low of $8.85 until finishing in the latest session at $9.83.
Guru’s Opinion on Sorrento Therapeutics Inc. [SRNE]:
B. Riley Securities have made an estimate for Sorrento Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 29, 2021. While these analysts kept the previous recommendation, Alliance Global Partners raised their target price to Buy. The new note on the price target was released on January 21, 2021, representing the official price target for Sorrento Therapeutics Inc. stock. Previously, the target price had yet another raise from $24 to $30, while H.C. Wainwright kept a Buy rating on SRNE stock.
The Average True Range (ATR) for Sorrento Therapeutics Inc. is set at 1.31, with the Price to Sales ratio for SRNE stock in the period of the last 12 months amounting to 68.35. The Price to Book ratio for the last quarter was 15.85.
SRNE Stock Performance Analysis:
Sorrento Therapeutics Inc. [SRNE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.13. With this latest performance, SRNE shares dropped by -29.58% in over the last four-week period, additionally plugging by 49.62% over the last 6 months – not to mention a rise of 359.35% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SRNE stock in for the last two-week period is set at 43.25, with the RSI for the last a single of trading hit 41.88, and the three-weeks RSI is set at 45.78 for Sorrento Therapeutics Inc. [SRNE]. The present Moving Average for the last 50 days of trading for this stock 10.64, while it was recorded at 9.08 for the last single week of trading, and 8.65 for the last 200 days.
Insight into Sorrento Therapeutics Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Sorrento Therapeutics Inc. [SRNE] shares currently have an operating margin of -503.99 and a Gross Margin at +51.68. Sorrento Therapeutics Inc.’s Net Margin is presently recorded at -746.41.
Return on Total Capital for SRNE is now -63.61, given the latest momentum, and Return on Invested Capital for the company is -93.64. Return on Equity for this stock declined to -244.90, with Return on Assets sitting at -49.06. When it comes to the capital structure of this company, Sorrento Therapeutics Inc. [SRNE] has a Total Debt to Total Equity ratio set at 102.57. Additionally, SRNE Total Debt to Total Capital is recorded at 50.63, with Total Debt to Total Assets ending up at 28.29. Long-Term Debt to Equity for the company is recorded at 86.32, with the Long-Term Debt to Total Capital now at 42.61.
Reflecting on the efficiency of the workforce at the company, Sorrento Therapeutics Inc. [SRNE] managed to generate an average of -$594,544 per employee. Receivables Turnover for the company is 2.66 with a Total Asset Turnover recorded at a value of 0.07.Sorrento Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.90 and a Current Ratio set at 0.90.
SRNE Stock EPS
With the latest financial reports released by the company, Sorrento Therapeutics Inc. posted -0.36/share EPS, while the average EPS was predicted by analysts to be reported at -0.2/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -80.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SRNE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sorrento Therapeutics Inc. go to 37.00%.
Sorrento Therapeutics Inc. [SRNE] Insider Position Details
There are presently around $697 million, or 28.80% of SRNE stock, in the hands of institutional investors. The top three institutional holders of SRNE stocks are: BLACKROCK INC. with ownership of 17,619,678, which is approximately 17.335% of the company’s market cap and around 15.71% of the total institutional ownership; STATE STREET CORP, holding 12,675,183 shares of the stock with an approximate value of $111.42 million in SRNE stocks shares; and VANGUARD GROUP INC, currently with $108.2 million in SRNE stock with ownership of nearly 10.875% of the company’s market capitalization.
Positions in Sorrento Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 135 institutional holders increased their position in Sorrento Therapeutics Inc. [NASDAQ:SRNE] by around 12,736,922 shares. Additionally, 82 investors decreased positions by around 5,681,165 shares, while 40 investors held positions by with 60,845,596 shares. The mentioned changes placed institutional holdings at 79,263,683 shares, according to the latest SEC report filing. SRNE stock had 54 new institutional investments in for a total of 2,270,365 shares, while 43 institutional investors sold positions of 1,331,755 shares during the same period.